Eva Wesley, Author at Born2Invest

Eva Wesley

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Eva Wesley

Stories By Eva Wesley

Asebio Welcomes the EU Biotech Act as a Boost to Competitiveness and Health Autonomy

Spain Joins First EU Joint Clinical Assessment Under New Health Technology Regulation

Johnson & Johnson’s Tecvayli Combo Shows Breakthrough Results in Multiple Myeloma

EFPIA Calls for Clearer AI Governance to Safely Transform Drug Development

Spain Prioritizes Clinical Benefit Over Efficiency in Funding New Cancer Drugs

Angelini Ventures Signs €150 Million EIB Deal to Accelerate Biotech Innovation in Europe

NurExone’s Exosome Platform Gains Global Spotlight with Dual 2025 Award Nominations

Pharma-Biotech Program Showcases Spanish Innovation and Strengthens Biomedical Collaboration

ImmunoPET Emerges as a Promising Virtual Biopsy for Personalizing Glioblastoma Treatment

EU Biotech Act Reaches Turning Point as Parliament Rewrites Report and Commission Splits Proposal